Myriad Genetics, Inc. (NASDAQ:MYGN) traded down 7.6% during mid-day trading on Friday . The company traded as low as $23.52 and last traded at $24.01. 1,345,233 shares traded hands during mid-day trading, an increase of 42% from the average session volume of 945,609 shares. The stock had previously closed at $25.99.

A number of equities research analysts have recently issued reports on the company. Barclays increased their target price on Myriad Genetics from $18.00 to $20.00 and gave the company an “underweight” rating in a research note on Friday. Zacks Investment Research lowered Myriad Genetics from a “hold” rating to a “sell” rating and set a $25.00 target price for the company. in a research note on Wednesday, May 29th. Needham & Company LLC reiterated a “strong-buy” rating and issued a $32.00 target price on shares of Myriad Genetics in a research note on Tuesday, May 14th. They noted that the move was a valuation call. ValuEngine lowered Myriad Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Finally, BidaskClub upgraded Myriad Genetics from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Myriad Genetics currently has an average rating of “Hold” and an average price target of $38.41.

The company has a debt-to-equity ratio of 0.24, a current ratio of 3.15 and a quick ratio of 2.86. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 20.01, a P/E/G ratio of 1.46 and a beta of 0.79.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.04). Myriad Genetics had a net margin of 2.62% and a return on equity of 9.82%. The business had revenue of $216.60 million for the quarter, compared to analyst estimates of $217.76 million. During the same quarter last year, the business earned $0.34 EPS. Myriad Genetics’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, research analysts forecast that Myriad Genetics, Inc. will post 1.44 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in Myriad Genetics by 6.4% during the 4th quarter. BlackRock Inc. now owns 12,202,442 shares of the company’s stock valued at $354,727,000 after purchasing an additional 735,832 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of Myriad Genetics by 0.6% in the 1st quarter. Baillie Gifford & Co. now owns 9,540,586 shares of the company’s stock worth $316,747,000 after acquiring an additional 55,642 shares in the last quarter. Vanguard Group Inc grew its position in shares of Myriad Genetics by 4.4% in the 3rd quarter. Vanguard Group Inc now owns 8,656,933 shares of the company’s stock worth $398,219,000 after acquiring an additional 365,697 shares in the last quarter. D. E. Shaw & Co. Inc. grew its position in shares of Myriad Genetics by 0.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 3,922,852 shares of the company’s stock worth $114,037,000 after acquiring an additional 29,874 shares in the last quarter. Finally, Frontier Capital Management Co. LLC grew its position in shares of Myriad Genetics by 4.4% in the 1st quarter. Frontier Capital Management Co. LLC now owns 3,363,970 shares of the company’s stock worth $111,684,000 after acquiring an additional 140,404 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Myriad Genetics (NASDAQ:MYGN) Shares Down 7.6%” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/myriad-genetics-nasdaqmygn-shares-down-7-6/3041936.html.

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Article: Why does a company issue an IPO?

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.